<DOC>
	<DOC>NCT01300156</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).</brief_summary>
	<brief_title>Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Previously histologically confirmed Hodgkin's lymphoma Failure to achieve a complete remission with the initial induction chemotherapy, or recurrent disease Performance status (ECOG) ≤ 3 Age ≤ 75 years old Number of prior chemotherapies: one or two regimens At least one or more unidimensionally measurable lesion(s) defined as; ≥ 2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination Adequate organ functions defined as; ANC &gt; 1,500/ul, platelet &gt; 75,000/ul, transaminases &lt; 3 X upper normal values; bilirubin &lt; 2 mg/dL Written informed consent approved by institutional review board or ethic committee Previous high dose chemotherapy with autologous stem cell transplantation or allogeneic stem cell transplantation Previous chemotherapies with ESHAP regimen Any other malignancies within the past 5 years except skin basal cell carcinoma or carcinoma in situ of cervix Other serious illness or medical conditions Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry History of significant neurologic or psychiatric disorders including dementia or seizures Active uncontrolled infection (viral, bacterial or fungal infection) Other serious medical illnesses Pregnancy or breastfeeding, women of childbearing potential not employing adequate contraception Previous history of drug allergy to one of the drugs in the study regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hodgkin's disease</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>refractory</keyword>
</DOC>